Tocilizumab: An updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-Mediated diseases

Clinical Medicine Insights: Therapeutics

Volumn 5, Issue , 2013, Pages 33-52

  Tanaka, Toshio ^a,b   Ogata, Atsushi ^a,b   Narazaki, Masashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Anti IL 6 receptor antibody; IL 6; Immune mediated diseases; Rheumatoid arthritis; Tocilizumab

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; TOCILIZUMAB;

ADULT ONSET STILL DISEASE; AMYLOIDOSIS; BEHCET DISEASE; CROHN DISEASE; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; MOLECULAR PATHOLOGY; MYELOOPTIC NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; POLYMYOSITIS; PROTEIN FUNCTION; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; UVEITIS; VASCULITIS;

EID: 84874220237     PISSN: 1179559X     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMT.S9282     Document Type: Review

References (276)

1. Kishimoto T. Interleukin-6: from basic sciences to medicine-40 years in immunology. Annu Rev Immunol. 2005;23:1-21.
2. Zilberstein A, Ruggieri R, Korn JH, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 1986;5:2529-37.
3. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73-6.
4. Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16:989-97.
5. Hirano T, Taga T, Yasukawa K, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 1987;84:228-31.
6. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360-7.
7. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339-42.
8. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989;86:7547-51.
9. Ohzato H, Yoshizaki K, Nishimoto N, et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery. 1992;111:201-9.
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
11. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-36.
12. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-6.
13. Liuzzi JP, Lichten LA, Rivera S, et al. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A. 2005;102:6843-8.
14. Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood. 1990;75:1602-5.
15. Hurst SM, Wilkinson TS, McLoughlin RM, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-14.
16. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-8.
17. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
18. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830-35.
19. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543-9.
20. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985;82:5490-4.
21. Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11: 88-95.
22. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activation of NF-kappa B in mouse calvariae. J Immunol. 2002;169:3353-62.
23. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88-91.
24. Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol. 2011;335:14-29.
25. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521-9.
26. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86:6367-71.
27. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Investig Dermatol. 1991;97:686-92.
28. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-54.
29. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573-81.
30. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120-6.
31. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003;300:2101-4.
32. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992;258:593-7.
33. Garbers C, Hermanns HM, Schaper F, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23: 85-97.
34. Aoki Y, Narazaki M, Kishimoto T, Tosato G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus. Blood. 2001;98:3042-9.
35. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 1992;127:25-50.
36. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A. 1993;90:10193-7.
37. Matsushita K, Takeuchi O, Standley DM, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009;458:1185-90.
38. Iwasaki H, Takeuchi O, Teraguchi S, et al. The IkB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol. 2011;12: 1167-75.
39. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199-219.
40. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53: 851-6.
41. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959-64.
42. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6:843-54.
43. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3: 81-9.
44. Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4:387-97.
45. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187:461-8.
46. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNFalpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002;169:1459-66.
47. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57-79.
48. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 2012;79:85-7.
49. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. T{stroke}ocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): result of phase 2, international multicentre randomized double-blind placebo-controlled trial. Ann Rheum Dis. 2012;71(Suppl 3):110.
50. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
51. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66: 1162-7.
52. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
53. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987-97.
54. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate: results from a substudy of the multicenter double-blind, placebo controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33-43.
55. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
56. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23.
57. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609-21.
58. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71:687-93.
59. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72: 43-50.
60. Bykerk VP, Ostör AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012;71:1950-4.
61. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic DMARDs: 24-week results of an open-label, clinical practice study (ACT-STAR). Arthritis Care Res (Hoboken). Sep 12, 2012. [Epub ahead of print.].
62. Hetland ML, Christensen IJ, Tarp U, et al. All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
63. Sakai R, Tanaka M, Nanki T, et al. For the REAL Study Group. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012;71:1820-6.
64. Nishimoto N. Japanese MRA study group for RA. Drug free remission after cessation of actemra monotherapy (DREAM Study). Ann Rheum Dis. 2010;69(Suppl 3):98.
65. Nishimoto N. Japanese MRA study group for RA. Retreatment efficacy and safety to tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE study). Ann Rheum Dis. 2010;69(Suppl 3):537.
66. Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, et al. The length of remission and rate of relapse after tocilizumab withdrawal in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(Suppl 3):69.
67. Fusama M, Nakahara H, Hamano Y, et al. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with t{stroke}ocilizumab. Mod Rheumatol. Jun 6, 2012. [Epub ahead of print.].
68. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 2012;51:1860-9.
69. Miwa Y, Furuya H, Yanai R, et al. Comparison of efficacy of four biological agents for rheumatoid arthritis patients using the HRQoL questionnaire and depression scale. Ann Rheum Dis. 2012;71(Suppl 3):663.
70. Foti R, Russo R, Malavolta N, et al. Effects of tocilizumab in combination with non biologic DMARDs on early improvement of anemia and fatigue in adult patients with moderate to severe active rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 3):671.
71. Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol. 2012;39:60-2.
72. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-32.
73. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:R141.
74. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011:Article ID 765624.
75. Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2499-503.
76. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the antiinterleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63:1255-64.
77. Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cells. Ann Rheum Dis. 2011;70:1507-10.
78. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989-2003.
79. Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum. 2012;42:281-96.
80. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. 2011:721608.
81. O'Reilly S, Ciechomska M, Cant R, Hugle T, van Larr JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev. 2012;23:99-107.
82. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998;25:308-13.
83. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001;27:140-6.
84. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestation. Arthritis Res Ther. 2009;11:R147.
85. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profiles in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotype. Plos One. 2009;4:e5903.
86. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71:1235-42.
87. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol. 1992;19:1207-11.
88. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology. 1993;61:239-46.
89. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy. 1994;73:493-6.
90. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol. 2006;126:561-8.
91. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest. 1999;102: 1253-60.
92. Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis. 2011;70:368-72.
93. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011;63:3575-85.
94. Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;80: 165-76.
95. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010;49:2408-12.
96. Kuwahara Y, Shima Y, Shirayama D, et al. Quantification of hardness, elastic and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Rheumatology (Oxford). 2008;47:1018-24.
97. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-37.
98. Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum. 1994;37:1744-51.
99. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865-74.
100. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 1998;24:73-9.
101. Sugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000;164:6593-600.
102. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol. 2006;176:9-15.
103. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60: 2505-12.
104. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. T{stroke}herapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50:1344-6.
105. Langford CA. Vasculitis. J Allergy Clin Immunol. 2010;125:S216-25.
106. Sharma P, Sharma S, Baltaro R, Hurley J. Systemic vascultis. Am Fam Physician. 2011;83:556-65.
107. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234-45.
108. Mason JC. Takayasu arteritis-advances in diagnosis and management. Nat Rev Rheumatol. 2010;6:405-15.
109. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456-8.
110. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36: 1286-94.
111. Caplanne D, Le Parc JM, Alexandre JA. Interleukin-6 in clinical relapses of polymyalgia and giant cell arteritis. Ann Rheum Dis. 1996;55:403-4.
112. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041-8.
113. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835-41.
114. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation. 1999;100:55-60.
115. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006;45:545-8.
116. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissueinfiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest. 1994;94:1134-40.
117. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia and giant cell arteritis. Ann Intern Med. 1994;121:484-91.
118. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43: 294-301.
119. Seko Y, Sato O, Takagi A, et al. Restricted usage of T-cell receptor ValphaVbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation. 1996;93:1788-90.
120. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58:1197-200.
121. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.
122. Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70:1874-5.
123. Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011;38:2080-1.
124. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51: 151-6.
125. Vinit J, Bielefeld P, Muller G, Besancenot JF. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine. 2012;79:317-8.
126. Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Reports. Jun 30, 2011:2011.
127. Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol. 2012;31:1263-5.
128. Salvarani C, Magnani L, Catanoso M, et al. Rescue treatment with t{stroke}ocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S90-3.
129. Bredemeier M, Rocha C, Barbosa M, Pitrez E. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012;30(1 Suppl 70): S98-100.
130. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Res Care. 2012;64:1720-9.
131. Lurati A, Bertani L, Re KA, Marrazza M, Bompane D, Scarpellini M. Successful treatment of a patient with giant cell vasculitis (horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Report Rheumatol. 2012:639612.
132. Isik M, Kilic L, Dogan I, Calquneri M. Tocilizumab for giant cell arteritis: an amazing result. Rheumatol Int. Sep 11, 2012. [Epub ahead of print.]
133. Cohen C, Mekinian A, Saidenberg-Kermanach N, et al. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis. 2012;71:628-9.
134. Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford). 2011;50:1928-30.
135. Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis. 2010;69:263-69.
136. Zen-Nyoji A, Shimizu H, Ohtani K, Oshimoto K, Kobayashi Y, Mori M. Increased RAHA titer and interleukin-6 levels in the synovial fluid in a patient with polymyalgia rheumatica. Intern Med. 1993;32:484-6.
137. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010;62:3768-75.
138. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-8.
139. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during long-term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39:552-7.
140. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010;37: 1075-6.
141. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027-32.
142. Obermoser G, Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus. 2010;19:1012-9.
143. Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol. 2011;23: 444-8.
144. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13:339-43.
145. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol. 1991;147: 117-23.
146. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus. 1996;5:571-5.
147. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L. Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565-70.
148. Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol. 1993;40:16-21.
149. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990;33:644-9.
150. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum. 1996;39:379-85.
151. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum. 1991;34:276-86.
152. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992;88:75-83.
153. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice. Am J Pathol. 1994;144:927-37.
154. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/ NZW F1 mice. J Clin Invest. 1994;94:585-91.
155. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998;112:397-402.
156. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119:296-305.
157. Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A. 2009;106:20423-8.
158. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52.
159. Maeshima K, Ishii K, Torigoe M, et al. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus. 2012;21:1003-6.
160. Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18:92-5.
161. Rapini RP, Warner NB. Relapsing polychondritis. Clin Dermatol. 2006;24: 482-5.
162. Lahmer T, Treiber M, von Werder A, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmu Rev. 2010;9:540-6.
163. Arnaud L, Devilliers H, Peng SL, et al. The relapsing polychondritis disease activity index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev. 2012;12:204-9.
164. Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum. 2004;50:3663-7.
165. Kemta Lekpa F, Kraus VB, Chevalier X. Biologics in relapsing polychondritis: a literature review. Semin Arthritis Rheum. 2012;41: 712-9.
166. Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford). 2009;48:318-9.
167. Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology (Oxford). 2012;51: 952-23.
168. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
169. Ratelade J, Verkman AS. Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012;44: 1519-30.
170. Benarroch EE. Aquaporin-4, homeostatis, and neurologic disease. Neurology. 2007;69:2266-8.
171. Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256:2082-4.
172. Icoz S, Tuzun E, Kurtuncu M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 2010;120:71-5.
173. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16: 1443-52.
174. Wang H, Wang K, Zhong X, et al. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation. 2012;19:304-8.
175. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108:3701-6.
176. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. Jul 11, 2012. Epub ahead of print.
177. Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with t{stroke}ocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch Neurol. Dec 24, 2012. [Epub ahead of print.
178. Shanahan F. Crohn's disease. Lancet. 2002;359:62-9.
179. Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy. 2011;3:1341-52.
180. Holub MC, Mako E, Devay T, et al. Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998;228:47-50.
181. Hosokawa T, Kusugami K, Ina K, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol. 1999;14:987-96.
182. Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis. 2000;15:206-10.
183. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164: 4878-82.
184. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-96.
185. Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol. 2007;3:328-35.
186. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22:773-92.
187. Scheinberg MA, Chapira E, Fernades ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol. 1996;14:653-5.
188. Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferongamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol. 1998;25:396-8.
189. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398-404.
190. Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol. 2003;30:2422-7.
191. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002;46: 3388-9.
192. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19:69-72.
193. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adultonset Still's disease. Ann Rheum Dis. 2009;68:153-4.
194. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28:485-7.
195. Cunha ML, Wagner J, Osawa A, Scheinberg M. The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. Rheumatology (Oxford). 2010;49:1014-6.
196. Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29:1191-4.
197. Yoshimura M, Makiyama J, Koga T, Miyashita T, Izumi Y, Torigoshi T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol. 2010;28:141-2.
198. Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adultonset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol. 2010;29:1465-7.
199. Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still'sdisease. Clin Rheumatol. Sep 15, 2010. [Epub ahead of print.].
200. Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011;21: 215-8.
201. Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31:1653-6.
202. Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still's diseases with aseptic meningitis-efficacy of interleukin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011;40:365-8.
203. Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adultonset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade. Ann Rheum Dis. 2011;70:390-2.
204. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92-6.
205. Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011;63:155-9.
206. Sekkach Y, Elqatni M, Khattabi AE, et al. Antagonists of interleukin-6 (tocilizumab) in adult refractory still disease. Presse Med. 2011;40: e333-7.
207. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22:712-9.
208. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, MatucciCerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010;6:417-29.
209. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-71.
210. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-9.
211. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314:363-9.
212. Hagihara K, Nishikawa T, Sugamata Y, et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005;10:1051-63.
213. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized antiinterleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426-35.
214. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50: 1761-9.
215. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-32.
216. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997-3000.
217. Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009;68:1235-6.
218. Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009;28:1113-6.
219. Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195-7.
220. De La Torre M, Arboleya L, Pozo S, Pinto J, Velasco J. Rapid and sustained response to tocilizumab, amti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus. 2011;4:178-80.
221. Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis. Amyloid. 2011;18:235-9.
222. Hattori Y, Ubara Y, Sumida K, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012;19:37-40.
223. Tanaka T, Hagihara K, Hishitani Y, Ogata A. Tocilizumab for the treatment of AA amyloidosis. In: Guvenc IA, editor. Amyloidosis-An insight to disease of systems and novel therapies. Croatia: INTECH Open Access Publisher; 2011:155-70.
224. Mendes D, Correia M, Barbedo M, Vaio T, Mota M. Behcet's disease-a contemporary review. J Autoimmun. 2009;32:178-88.
225. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL-6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol. 1992;140:410-9.
226. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544-9.
227. Yamakawa Y, Sugita Y, Nagatani T, et al. Interleukin-6 (IL-6) in patients with Behcet's disease. J Dermatol Sci. 1996;11:189-95.
228. Kulaber A, Tugal-Tutkun I, Yentur SP, et al. Pro-inflammatory cellular immune response in Behcet's disease. Rheumatol Int. 2007;27:1113-8.
229. Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298-302.
230. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome. Clin Immunol Immunopathol. 1997;82:12-7.
231. Akman-Demir G, Turun E, Icoz S, et al. Interleukin-6 in neuro-Behcet's disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373-6.
232. Borhani Haghighi A, Ittehadi H, Nikseresht AR, et al. CSF levels of cytokines in neuro-Behcet's disease. Clin Neurol Neurosurg. 2009;111:507-10.
233. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuroBehcet's disease, the first report. Clin Neurol Neurosurgery. 2012;114: 297-8.
234. Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010;120:3073-83.
235. Murray PI, Hoekzema R, van Haren MA, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmos Vis Sci. 1990;31: 917-20.
236. Benson MT, Shepherd L, Rees RC, Rennie IG. Production of interleukin-6 by human retinal pigment epithelium in vitro and its regulation by other cytokines. Curr Eye Res. 1992;11(Suppl):173-9.
237. Norose K, Yano A, Wang XC, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:33-9.
238. Petrinovic-Doresic J, Mazuran R, Henc-Petrinovic L, Kuzmanovic B, Jovicic A. Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm. 1999;7:75-84.
239. Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye and ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12:193-201.
240. Yoshimura T, Sonoda K, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48:347-54.
241. Hohki S, Ohguro N, Haruta H, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010;91:162-70.
242. Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011;52: 3264-71.
243. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382-3.
244. Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Onocol. 2010;28:e602-4.
245. Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant. 2011;17:1862-8.
246. Nishida S, Kawasaki T, Kashiwagi H, et al. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod Rheumatol. 2011;21:420-2.
247. Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol. 2004;80:246-9.
248. Yuzuriha A, Saitoh T, Koiso H, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by antiinterleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 2011;126:147-50.
249. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, OcanaMedina C, Sanchez-Roman J. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012;51:1918-9.
250. Tanaka T, Hagihara K, Shima Y, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford). 2010;49:824-6.
251. Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol. 2010:Article ID 720305.
252. Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol. 2009;90:99-102.
253. Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels. 2010;25:444-7.
254. Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011;63:1151-5.
255. Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol. 2011;128:1128-30.
256. Schanz S, Schmalzing M, Guenova E, et al. Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol. 2012;148:17-20.
257. Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012;21:2079-84.
258. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010;69:2217-8.
259. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine. 2010;77:624-5.
260. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010;77:625-6.
261. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized antiinterleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol. 2011;21:436-9.
262. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol. 2011;38:1527.
263. Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009;61:1762-4.
264. Kwan K, Bharadwaj S, Inderjeeth C. Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus GalmetteGuerin unresponsive to DMARDs. Int J Rheum Dis. 2012;15:e73-5.
265. Sieper J, Inman RD, Badalamenti S, Radin A, Braun J. Sarilumab for the treatment of ankylosing spondylitis: results of phase 2, randomized doubleblind, placebo-controlled, international study (ALIGN). Ann Rheum Dis. 2012;71(Suppl 3):111.
266. Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, t{stroke}ocilizumab. Ann Rheum Dis. 2011;70:1164-5.
267. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5:e14328.
268. Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with t{stroke}ocilizumab. Rheumatol Int. 2012;32:4041-4015.
269. Matthijs Boekholdt S, Stores ESG. The interleukin-6 pathway and atherosclerosis. Lancet. 2012;379:1176-8.
270. Qin Z, Keamey P, Plaisance K, Parsons CH. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leukoc Biol. 2010;87:25-34.
271. Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature. 1988;333:776-8.
272. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988;241:1652-5.
273. Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med. 1994;179:961-71.
274. Ambrosino C, Ruocco MR, Chen X, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem. 1997;272:14883-92.
275. Mahe Y, Mukaida N, Kuno K, et al. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem. 1991;266:13759-63.
276. Ohno H, Kaneko S, Lin Y, Kobayashi K, Murakami S. Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol. 1999;58:11-8.